REG - Diaceutics PLC - Director/PDMR/PCA Shareholding & TR1
02/04/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB8170Ia&default-theme=true
RNS Number : 8170I Diaceutics PLC 02 April 2024
Director / PDMR / PCA Shareholding & TR-1 Notification
Belfast and London, 2 April 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry,
announces that on 28 March 2024, Peter Keeling, co-founder and Executive
Director of Diaceutics, and Delia Keeling (Peter Keeling's spouse and a PCA),
cumulatively sold 1,500,000 ordinary shares of £0.002 each in the Company
("Ordinary Shares") at a price of 102 pence per Ordinary Share. As a result
of the sale, Peter and Delia Keeling's combined shareholding in Diaceutics is
15,752,049 Ordinary Shares representing approximately 18.60% of the Company's
issued share capital.
This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance
with the Company's obligations under Article 17 of MAR. The person responsible
for making this announcement on behalf of the Company is Nick Roberts, Chief
Financial Officer.
Enquiries:
Diaceutics PLC
Ryan Keeling, Chief Executive Officer Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer investorrelations@diaceutics.com
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Strategic Communications Tel: +44(0)20 3405 0205
Caroline Forde, Kinvara Verdon, Kieran Breheny diaceutics@almastrategic.com
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Peter Keeling
2 Reason for notification
a. Position/Status Executive Director
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Sale
c. Price(s) and volume(s)
Price(s) Volume(s)
£1.02 750,000
d. Date of the transaction 28 March 2024
e. Place of the transaction AIM Market of the London Stock Exchange
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Delia Keeling
2 Reason for notification
a. Position/Status PCA
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of £0.002 each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Sale
c. Price(s) and volume(s)
Price(s) Volume(s)
£1.02 750,000
d. Date of the transaction 28 March 2024
e. Place of the transaction AIM Market of the London Stock Exchange
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the underlying issuer of existing shares to Diaceutics PLC ORD GBP0.002
which voting rights are attached (ii):
1b. Please indicate if the issuer is a non-UK issuer (please mark with an
"X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with
an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) (iii):
3. Details of person subject to the notification obligation (iv)
Name Peter & Delia Keeling
City and country of registered office (if applicable) NA
4. Full name of shareholder(s) (if different from 3.) (v)
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached (vi): 28 March, 2024
6. Date on which issuer notified: 28 March, 2024
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) (vii)
(total of 8.B 1 + 8.B 2)
Resulting situation on the date on which threshold was crossed or reached 18.60% 18.60%
Position of previous notification (if applicable) 20.37% 20.37%
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights (ix) % of voting rights
shares
ISIN code (if possible)
Direct Indirect Direct Indirect
(DTR5.1) (DTR5.2.1) (DTR5.1) (DTR5.2.1)
GB00BJQTGV64 15,752,049 18.60%
SUBTOTAL 8. A 15,752,049
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration Exercise/ Number of voting rights that may be acquired if the instrument is % of voting rights
date (x)
Conversion Period (xi)
exercised/converted.
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R
(1) (b)
Type of financial instrument Expiration Exercise/ Physical or cash Number of voting rights % of voting rights
date (x)
Conversion Period (xi)
Settlement (xii)
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification
obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural
person or legal entity and does not control any other undertaking(s) holding
directly or indirectly an interest in the (underlying) issuer (xiii)
Full chain of controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional rows as
necessary) (xiv)
Name (xv) % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher Total of both if it equals or is higher than the notifiable threshold
than the notifiable threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information (xvi)
Place of completion AIM Stock Exchange, London
Date of completion 28, March 2024
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUWVWRSOUOUARRecent news on Diaceutics
See all newsREG - Diaceutics PLC - Appointment of Amie Mc Neice as VP of Marketing
AnnouncementREG - Diaceutics PLC - Block Listing Return
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan
AnnouncementREG - Diaceutics PLC - Director/PDMR/PCA Shareholding & TR1
AnnouncementRCS - Diaceutics PLC - Significant upgrade to Diaceutics' DXRX platform
Announcement